tiprankstipranks
Trending News
More News >
BioArctic AB Class B (SE:BIOA.B)
:BIOA.B

BioArctic AB Class B (BIOA.B) AI Stock Analysis

Compare
1 Followers

Top Page

SE

BioArctic AB Class B

(Frankfurt:BIOA.B)

Rating:61Neutral
Price Target:
kr208.00
▲(14.35%Upside)
BioArctic AB's stock score is primarily influenced by its financial performance and technical analysis. The company's financial health shows significant weaknesses, especially in earnings and cash flows, which are critical for sustained growth. Technical indicators offer some positive signs, with the stock showing short-term momentum. Valuation appears balanced, aligning with industry norms, but the lack of a dividend yield is a downside for certain investors.

BioArctic AB Class B (BIOA.B) vs. iShares MSCI Sweden ETF (EWD)

BioArctic AB Class B Business Overview & Revenue Model

Company DescriptionBioArctic AB Class B (BIOA.B) is a Swedish research-based biopharmaceutical company engaged in the development of innovative treatments for central nervous system disorders. The company focuses on diseases with a high unmet medical need, such as Alzheimer's disease and Parkinson's disease. BioArctic's core products are based on its proprietary technology platforms, which include antibodies and other biologics designed to address neurodegenerative conditions.
How the Company Makes MoneyBioArctic AB generates revenue through a combination of research and development collaborations, milestone payments, and potential royalties from its partnerships with major pharmaceutical companies. The company engages in strategic alliances with leading firms to co-develop and commercialize its drug candidates, which allows it to leverage external expertise and resources while sharing the financial risks and rewards. Key partnerships, such as those with Eisai Co., Ltd., play a significant role in advancing BioArctic's product pipeline and contributing to its earnings. The company also seeks to monetize its proprietary technology platforms by licensing them to other biopharmaceutical companies.

BioArctic AB Class B Financial Statement Overview

Summary
BioArctic AB's financial performance shows considerable weaknesses, particularly in revenue generation and cash flow management, impacting its profitability and growth potential. Despite a solid equity base and low leverage, the negative trends in earnings and cash flows underscore the need for strategic interventions to reverse the downturn and enhance financial health.
Income Statement
45
Neutral
BioArctic AB has experienced significant volatility in its income statement metrics. The company reported a substantial decrease in total revenue in 2024 compared to 2023, alongside a negative EBIT and net income. Gross and net profit margins have deteriorated, indicating operational challenges. Despite previous revenue growth, the recent decline raises concerns about sustainable growth.
Balance Sheet
65
Positive
The balance sheet reflects a strong equity position with low debt levels, resulting in a favorable debt-to-equity ratio. However, the return on equity has been negative due to persistent net losses. The equity ratio remains robust, suggesting financial stability despite recent operational setbacks.
Cash Flow
40
Negative
Cash flow metrics reveal significant pressure, with a negative operating cash flow in 2024 compared to positive flows in previous years. The free cash flow has also turned negative, indicating liquidity challenges. This trend highlights the need for improved cash management and operational efficiency to support future growth.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
257.35M616.00M228.29M23.15M62.35M
Gross Profit
230.37M526.37M153.97M-31.92M12.11M
EBIT
-228.51M252.64M-10.16M-139.72M-82.32M
EBITDA
-165.13M295.29M4.22M-126.42M-74.58M
Net Income Common Stockholders
-177.08M229.25M-11.18M-119.79M-68.52M
Balance SheetCash, Cash Equivalents and Short-Term Investments
512.93M1.11B805.39M848.40M999.94M
Total Assets
1.11B1.19B858.31M897.73M1.05B
Total Debt
54.23M4.98M10.04M15.88M20.77M
Net Debt
-458.70M-606.59M-795.35M-832.53M-979.17M
Total Liabilities
216.74M139.50M72.06M109.05M143.01M
Stockholders Equity
894.94M1.05B786.24M788.68M907.30M
Cash FlowFree Cash Flow
-316.33M302.25M-44.38M-144.84M-104.81M
Operating Cash Flow
-316.33M309.69M-31.64M-140.46M-92.34M
Investing Cash Flow
205.63M-507.49M-12.76M-4.41M-12.52M
Financing Cash Flow
5.69M14.06M-2.81M-7.39M-6.60M

BioArctic AB Class B Technical Analysis

Technical Analysis Sentiment
Positive
Last Price181.90
Price Trends
50DMA
181.28
Positive
100DMA
199.96
Positive
200DMA
186.42
Positive
Market Momentum
MACD
2.77
Negative
RSI
61.52
Neutral
STOCH
83.78
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOA.B, the sentiment is Positive. The current price of 181.9 is below the 20-day moving average (MA) of 183.20, above the 50-day MA of 181.28, and below the 200-day MA of 186.42, indicating a bullish trend. The MACD of 2.77 indicates Negative momentum. The RSI at 61.52 is Neutral, neither overbought nor oversold. The STOCH value of 83.78 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BIOA.B.

BioArctic AB Class B Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
kr17.81B19.7460.96%501.62%
54
Neutral
$5.31B3.29-45.39%2.79%16.77%-0.07%
52
Neutral
kr3.56B0.30-15.21%-75.91%
50
Neutral
kr2.51B-45.80%-0.57%-39.92%
47
Neutral
kr1.16B-42.24%-19.44%
45
Neutral
kr2.19B-40.15%63.85%
42
Neutral
kr1.64B
9.53%41.19%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:BIOA.B
BioArctic AB Class B
201.20
-30.00
-12.98%
SE:HNSA
Hansa Biopharma AB
24.20
-28.25
-53.86%
SE:BINV
BioInvent International AB
38.10
2.80
7.93%
SE:FLERIE
InDex Pharmaceuticals Holding AB
45.65
-8.95
-16.39%
SE:VICO
Vicore Pharma Holding AB
9.35
-12.74
-57.67%
SE:XSPRAY
Xspray Pharma AB
31.30
-42.81
-57.77%

BioArctic AB Class B Corporate Events

BioArctic AB Unveils Strategic Vision for 2030 at Capital Markets Day
Jun 2, 2025

BioArctic AB held its Capital Markets Day 2025, outlining its strategic goals for 2030, which include expanding its pipeline, forming global partnerships, and launching Leqembi® for Alzheimer’s in the Nordics. The company aims to leverage its strong financial position, innovative research platforms, and successful partnerships to drive growth and profitability, positioning itself as a leading pharmaceutical entity in Sweden.

BioArctic AB Issues New Shares Under Stock Option Program
May 30, 2025

BioArctic AB announced the issuance of 3,000 Class B shares as part of its 2019/2028 stock option program, bringing the total number of shares to 88,531,485. This move reflects the company’s ongoing commitment to rewarding its stakeholders and maintaining a robust capital structure, with implications for its market positioning and shareholder engagement.

BioArctic AB Annual General Meeting Resolutions and New Incentive Program
May 22, 2025

At its Annual General Meeting, BioArctic AB resolved to carry forward SEK 889,598,575 without paying dividends for 2024, re-elected its board members, and approved remuneration for them. The meeting also authorized the board to issue new shares and introduced a three-year incentive program for employees, which includes performance-based share units contingent on meeting specific conditions related to shareholder returns, operational targets, and sustainability goals.

BioArctic Gains EU Orphan Designation for MSA Treatment
May 22, 2025

BioArctic AB has received a positive opinion from the European Medicines Agency for orphan medicinal product designation for exidavnemab, a treatment for Multiple System Atrophy (MSA), a rare and fatal neurodegenerative disease. This designation provides incentives for developing treatments for rare diseases, potentially enhancing BioArctic’s market positioning and offering hope for addressing high unmet medical needs in MSA and related disorders.

BioArctic’s Q1 2025 Success: Leqembi’s Approval and Strategic Partnerships Boost Financial Performance
May 21, 2025

BioArctic AB reported significant financial growth in Q1 2025, driven by the approval and commercial success of its Alzheimer’s treatment, Leqembi, in the EU and other markets. The company also benefited from a lucrative license agreement with Bristol Myers Squibb, contributing to a substantial increase in net revenues and operating profit, positioning BioArctic as a key player in the neurodegenerative disease treatment market.

Eisai Projects Significant Growth for Alzheimer’s Drug Leqembi
May 15, 2025

Eisai, in partnership with BioArctic, projects significant revenue growth for their Alzheimer’s treatment, Leqembi, with sales expected to reach JPY 76.5 billion for fiscal year 2025. This growth reflects a 73% increase from the previous year, generating substantial royalties for BioArctic and strengthening their market position in Alzheimer’s treatment.

BioArctic AB to Present Q1 2025 Financial Results
May 13, 2025

BioArctic AB will release its first quarter report for 2025 on May 21, inviting investors, analysts, and media to an audiocast and teleconference where the CEO and CFO will present and discuss the results. This event reflects BioArctic’s ongoing commitment to transparency and engagement with stakeholders, potentially impacting its market perception and investor relations.

BioArctic Expands Exidavnemab Study to Include MSA Patients
May 8, 2025

BioArctic AB has expanded its Phase 2a EXIST study to include Multiple System Atrophy (MSA) patients, following regulatory approval in Spain and Poland. This expansion marks a significant step in developing exidavnemab, a monoclonal antibody targeting alpha-synuclein aggregates, as a potential treatment for MSA and Parkinson’s, addressing a high unmet medical need in neurodegenerative diseases.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.